Our dedicated team is self-contained with a mandate for independent decision making on new and existing investments.

We make investments in life science companies aiming to create value by fostering innovation, guiding successful businesses and generating financial return to Roche.

An investment is more than a funding round to us: an investment means a proactive and long-term engagement.

We invest in private companies with innovative medicines, diagnostics and technologies. In select cases, we will invest in companies alongside research and development collaborations with Roche or Genentech.

We share Roche's culture of innovation. We are global, forward looking and willing to take risks on innovations with high potential reward.

We focus on Series A investments though we will invest later. For therapeutics, we like to invest in preclinical companies. For diagnostics, we prefer 12-18 months to launch.

The amount of the investment depends on the size of the financing round. In general, we will invest CHF 3-10 million in the first financing round with a 15% ownership stake but we do vary these when appropriate.

We are an evergreen fund and have reserves if and when follow-on financing rounds are needed.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.